ATLANTIC is a phase 2, open-label, single-arm trial that assessed the effect of durvalumab as a third-line or later treatment for advanced non-small cell lung cancer in patients with EGFR mutations or ALK rearrangements. The gene discussed is ALK; the disease is non-small cell lung carcinoma.